TrialDrug safety2018
Liver Safety of Fasiglifam (TAK-875) in Patients with Type 2 Diabetes: Review of the Global Clinical Trial Experience.
John F Marcinak et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this papercites it